Abstract: Provided are a novel immuno-optomagnetic point-of-care (PoC) assay and in particular, a method for detecting an analyte using magnetic nanoparticles and quantum dots (QD) having antibodies which are interfaced with the fabricated PoC biochip platform for quantitative analysis, and an immuno-optomagnetic detection method. The method also relates to methods of making such a plurality of conjugated magnetic quantum dot nanoparticles, methods of detecting analytes using such a plurality of conjugated quantum dot nanoparticles.

Abstract: Provided are a novel immuno-optomagnetic point-of-care (PoC) assay and in particular, a method for detecting an analyte using magnetic nanoparticles and quantum dots (QD) having antibodies which are interfaced with the fabricated PoC biochip platform for quantitative analysis, and an immuno-optomagnetic detection method. The method also relates to methods of making such a plurality of conjugated magnetic quantum dot nanoparticles, methods of detecting analytes using such a plurality of conjugated quantum dot nanoparticles.

Abstract: The present invention is directed to methods and a bio-capacitor sensing device for the detection of toxic chemicals using bacteria. The sensing platform comprises gold interdigitated capacitor with a defined geometry, a layer of carboxy-CNTs immobilized with viable E. coli cells as sensing elements. Also included are methods of making the bio-capacitor device and methods for detecting toxic chemicals that induce cellular stress response. The present innovation discloses the development of a bio capacitor chips immobilized with carboxy-CNTs tethered E. coli bacteria. In addition, the present invention also includes determination of behavior and characteristics of chemically stimulated bacteria on biochip using electric field including frequency and/or amplitude as controlling parameters.

Abstract: The present invention relates to novel formulations comprising ezetimibe as active ingredient. In particular the invention relates to a pharmaceutical composition comprising 5 to 20 wt-% ezetimibe, 50 to 85 wt-% diluent, 3 to 25 wt-% disintegrant, 1 to 10 wt-% binder, and 0.5 to 1 wt-% lubricant, characterized in that the ezetimibe has a particle size distribution of d(0.9) of 5 ?m to 35 ?m and d(0.5) of 3 ?m to 20 ?m, as well as methods for preparing said formulations.

Abstract: The present invention disclosed provides for a rugged, compact sensing device for various implementations including those of automotive, marine, and other combustion technologies that require low cost accurate pressure sensing during internal combustion engine process. In one or more aspects of the present invention, a MEMS sensor connection with a flexible circuit is presented and the communication of which is preferably achieved through the use of wire bond technology.

Abstract: The present invention relates to a process for the preparation of a medicament containing vardenafil hydrochloride trihydrate in solid form, in which vardenafil hydrochloride trihydrate is processed with suitable pharmaceutical auxiliaries at a temperature of from approx. 20° C. to approx. 45° C.

Abstract: A Micro-Electro-Mechanical System (MEMS) pressure sensor is disclosed, comprising a gauge wafer, comprising a micromachined structure comprising a membrane region and a pedestal region, wherein a first surface of the micromachined structure is configured to be exposed to a pressure medium that exerts a pressure resulting in a deflection of the membrane region. The gauge wafer also comprises a plurality of sensing elements patterned on the electrical insulation layer on a second surface in the membrane region, wherein a thermal expansion coefficient of the material of the sensing elements substantially matches with a thermal expansion coefficient of the material of the gauge wafer. The pressure sensor comprises a cap wafer coupled to the gauge wafer, which includes a recess on an inner surface of the cap wafer facing the gauge wafer that defines a sealed reference cavity that encloses and prevents exposure of the sensing elements to an external environment.

Abstract: The present invention disclosed provides for a rugged, compact sensing device for various implementations including those of automotive, marine, and other combustion technologies that require low cost accurate pressure sensing during internal combustion engine process. In one or more aspects of the present invention, a MEMS sensor connection with a flexible circuit is presented and the communication of which is preferably achieved through the use of wire bond technology.

Abstract: A method for separating a plurality of dies on a Micro-Electro-Mechanical System (MEMS) wafer comprising scribing a notch on a first side of the wafer between at least two of the plurality of dies on a first surface and depositing a metal on the first surface of the plurality of dies. The method further comprises scribing a second side of the wafer between at least two of the plurality of dies from a second surface thereof through the notch. The first side and second side are substantially parallel and opposite each other and the first surface and the second surface are substantially parallel and opposite each other. In a process in accordance with the present invention, a method to minimize chipping of the bonding portion of a MEMs device during sawing of the wafer is provided, which minimally affects the process steps associated with separating the die on a wafer.

Abstract: The present invention is directed to methods and a bio-capacitor sensing device for the detection of toxic chemicals using bacteria. The sensing platform comprises gold interdigitated capacitor with a defined geometry, a layer of carboxy-CNTs immobilized with viable E. coli cells as sensing elements. Also included are methods of making the bio-capacitor device and methods for detecting toxic chemicals that induce cellular stress response. The present innovation discloses the development of a bio capacitor chips immobilized with carboxy-CNTs tethered E. coli bacteria. In addition, the present invention also includes determination of behavior and characteristics of chemically stimulated bacteria on biochip using electric field including frequency and/or amplitude as controlling parameters.

Abstract: The present invention relates to an orally disintegrating dosage form containing aripiprazole. The formulation of the invention shows a fast disintegration.

Abstract: The present invention relates to novel formulations comprising ezetimibe as active ingredient. In particular the invention relates to a pharmaceutical composition comprising 5 to 20 wt-% ezetimibe, 50 to 85 wt-% diluent, 3 to 25 wt-% disintegrant, 1 to 10 wt-% binder, and 0.5 to 1 wt-% lubricant, characterized in that the ezetimibe has a particle size distribution of d(0.9) of 5 ?m to 35 ?m and d(0.5) of 3 ?m to 20 ?m, as well as methods for preparing said formulations.

Abstract: The present invention relates to a process for the preparation of a medicament containing vardenafil hydrochloride trihydrate in solid form, in which vardenafil hydrochloride trihydrate is processed with suitable pharmaceutical auxiliaries at a temperature of from approx. 20° C. to approx. 45° C.

Abstract: The present invention provides a controlled release pharmaceutical composition of an acid labile, poorly soluble drug having pH dependent solubility profile in aqueous environment. In a preferred embodiment the drug is combined with a practically water insoluble polymer an optimizing agent and optional additives to produce a controlled release of therapeutic agent when compositions is exposed to aqueous environment.

Abstract: A once-a-day controlled release drug delivery system of diltiazem hydrochloride is provided, which is bioequivalent in plasma profile of Cardizem CD. The fast, medium, and slow release fractions are prepared using various compositions and weight gains. The individual fill weights are computed and then are filled into the same capsule using specialized encapsulation equipment using a triple-filling process. A preferred membrane dispersion that is used for preparing the fast release fraction contains 0.2% of sodium lauryl sulfate along with 20% of water soluble plasticizer (triethyl citrate), and 2% silicone dioxide, based on quaternary polymethacrylate on the weight basis. This combination provides an initial pulsatile burst after a lag time of 2 hours, leading to in-vivo bioequivalence. The preferred membrane dispersion that is used for preparing the medium release and the slow release fractions contain 16% of water soluble plasticizer along with 5% silicone dioxide, based on quaternary polymethacrylate.

Abstract: An oral delivery system for the treatment of non-insulin dependent diabetes mellitus in humans includes a pharmaceutically effective amount of a biguanide and a water-insoluble polymeric carrier, providing for a controlled release of the biguanide independent of environmental pH. In addition, a layer including a glitazone or sulfonylurea can be included in the oral delivery system, while still providing for a pH-independent, controlled release of biguanide over an extended period of time.

Abstract: The present invention provides a controlled release pharmaceutical composition of an acid labile, poorly soluble drug having pH dependent solubility profile in aqueous environment. In a preferred embodiment the drug is combined with a practically water insoluble polymer an optimizing agent and optional additives to produce a controlled release of therapeutic agent when compositions is exposed to aqueous environment.

Abstract: A once-a-day controlled release drug delivery system of diltiazem hydrochloride is provided, which is bioequivalent in plasma profile of Cardizem CD. The fast, medium, and slow release fractions are prepared using various compositions and weight gains. The individual fill weights are computed and then are filled into the same capsule using specialized encapsulation equipment using a triple-filling process. A preferred membrane dispersion that is used for preparing the fast release fraction contains 0.2% of sodium lauryl sulfate along with 20% of water soluble plasticizer (triethyl citrate), and 2% silicone dioxide, based on quaternary polymethacrylate on the weight basis. This combination provides an initial pulsatile burst after a lag time of 2 hours, leading to in-vivo bioequivalence. The preferred membrane dispersion that is used for preparing the medium release and the slow release fractions contain 16% of water soluble plasticizer along with 5% silicone dioxide, based on quaternary polymethacrylate.

Abstract: The present invention provides the components for a stable felodipine composition and a process for preparing the composition. The composition includes felodipine, non-covalently bound to &bgr;-cylodextrin, and an optional binder as a moisture carrier component for the migration of hydroxide ions to the non-covalently bound felodipine and &bgr;-cylodextrin. The felodipine composition is combined with a carrier comprising cyclodextrin particles, a water-insoluble alkaline component and a swellable polymer.